The stock of Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) has increased by 2.35 when compared to last closing price of 1.70.Despite this, the company has seen a gain of 10.13% in its stock price over the last five trading days. Seeking Alpha reported 2024-05-05 that Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q1 2024 Earnings Conference Call May 2, 2024 5:00 PM ET Company Participants Lisa DeFrancesco – Head of Investor Relations and Strategy Lonnel Coats – Chief Executive Officer and Director Jeffrey Wade – President and Chief Financial Officer Craig Granowitz – Senior Vice President and Chief Medical Officer Tom Garner – Senior Vice President and Chief Commercial Officer Alan Main – Executive Vice President of Innovation & Chemical Sciences Conference Call Participants John Geelan – Piper Sandler Roanna Ruiz – Leerink Partners Andrew Tsai – Jefferies Joseph Stringer – Needham & Company Operator Good day, everyone, and welcome to the Lexicon Pharmaceuticals First Quarter 2024 Financial Results Conference Call. At this time all participants are in a listen-only mode.
Is It Worth Investing in Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Right Now?
Additionally, the 36-month beta value for LXRX is 1.37. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 3 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for LXRX is 239.50M and currently, short sellers hold a 8.40% ratio of that float. The average trading volume of LXRX on May 06, 2024 was 4.57M shares.
LXRX’s Market Performance
LXRX’s stock has seen a 10.13% increase for the week, with a -15.53% drop in the past month and a -18.31% fall in the past quarter. The volatility ratio for the week is 12.56%, and the volatility levels for the past 30 days are at 8.02% for Lexicon Pharmaceuticals Inc The simple moving average for the last 20 days is -1.12% for LXRX’s stock, with a simple moving average of 3.79% for the last 200 days.
Analysts’ Opinion of LXRX
Many brokerage firms have already submitted their reports for LXRX stocks, with Leerink Partners repeating the rating for LXRX by listing it as a “Outperform.” The predicted price for LXRX in the upcoming period, according to Leerink Partners is $5 based on the research report published on April 30, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see LXRX reach a price target of $3. The rating they have provided for LXRX stocks is “Hold” according to the report published on March 07th, 2023.
Piper Sandler gave a rating of “Overweight” to LXRX, setting the target price at $10 in the report published on August 12th of the previous year.
LXRX Trading at -17.89% from the 50-Day Moving Average
After a stumble in the market that brought LXRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.08% of loss for the given period.
Volatility was left at 8.02%, however, over the last 30 days, the volatility rate increased by 12.56%, as shares sank -15.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.58% lower at present.
During the last 5 trading sessions, LXRX rose by +10.13%, which changed the moving average for the period of 200-days by -20.18% in comparison to the 20-day moving average, which settled at $1.7437. In addition, Lexicon Pharmaceuticals Inc saw 13.73% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LXRX starting from COATS LONNEL, who purchase 90,000 shares at the price of $1.05 back on Nov 16 ’23. After this action, COATS LONNEL now owns 914,359 shares of Lexicon Pharmaceuticals Inc, valued at $94,797 using the latest closing price.
COATS LONNEL, the Chief Executive Officer of Lexicon Pharmaceuticals Inc, purchase 10,000 shares at $1.01 during a trade that took place back on Nov 10 ’23, which means that COATS LONNEL is holding 824,359 shares at $10,100 based on the most recent closing price.
Stock Fundamentals for LXRX
Current profitability levels for the company are sitting at:
- -80.46 for the present operating margin
- 0.82 for the gross margin
The net margin for Lexicon Pharmaceuticals Inc stands at -83.11. The total capital return value is set at -0.47. Equity return is now at value -101.92, with -66.24 for asset returns.
Based on Lexicon Pharmaceuticals Inc (LXRX), the company’s capital structure generated 0.26 points at debt to capital in total, while cash flow to debt ratio is standing at -1.83. The debt to equity ratio resting at 0.35. The interest coverage ratio of the stock is -29.37.
Currently, EBITDA for the company is -171.2 million with net debt to EBITDA at -0.05. When we switch over and look at the enterprise to sales, we see a ratio of 189.62. The receivables turnover for the company is 1.51for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.58.
Conclusion
In conclusion, Lexicon Pharmaceuticals Inc (LXRX) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
